Eli Lilly expects FDA decision on Zepbound for sleep apnea as early as end of year

Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year. If cleared by the Food and Drug Administration, the company plans to launch Zepbound for so-called obstructive … Read more

Weight loss drug contender Zealand Pharma jumps 23% on trial results

Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024.  Bloomberg | Bloomberg | Getty Images LONDON — Shares of Denmark’s Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced … Read more

More U.S. employers covering GLP-1s for weight loss

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. The injectable weight loss medication Wegovy at New City Halstead Pharmacy in Chicago on April 24, 2024. Scott Olson | Getty Images Good morning! More U.S. employers are covering a buzzy class of medications called GLP-1s for weight … Read more

Eli Lilly CFO Anat Ashkenazi on managing soaring demand for GLP-1s

A pharmacist holds boxs of Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.  George Frey | Bloomberg | Getty Images Skyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new heights over the last year. … Read more

Eli Lilly’s Alzheimer’s drug could help stock join the $1 trillion club

Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. To join the $1 trillion market capitalization club, it will need help from the bench — including an Alzheimer’s drug that moved one step closer to market this week. A key advisory panel for … Read more

FDA advisors recommend Eli Lilly Alzheimer’s drug donanemab

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty … Read more

Fed meeting and CPI report: Jim Cramer’s week ahead

CNBC’s Jim Cramer on Friday guided investors through next week’s most market-moving events, highlighting the Federal Reserve’s meeting and the latest consumer price index report. “I’d be careful making a big move before the Fed meeting. We can’t be sure if Jay Powell won’t be more emphatic about leaving rates higher for longer given this … Read more

AstraZeneca, drugmakers release promising cancer data

Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after spending the last weekend in … Read more

Alphabet CFO Anat Ashkenazi jumps from GLP-1 boom to generative AI

Alphabet incoming CFO Anat Ashkenazi, who spent 23 years at Eli Lilly Eli Lilly Alphabet’s outgoing finance chief, Ruth Porat, spent the past year and a half trying to help her internet company navigate the generative artificial intelligence boom. The person who was just named her successor was knee-deep in a very different phenomenon: anti-obesity … Read more

Why Jim Cramer says Ford must be ‘bought aggressively’ on the dip

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Wednesday’s key moments. The S & P 500 climbed Wednesday after a second round of weak jobs data pushed bond yields lower and gave the market hope for Federal Reserve interest rate cuts … Read more